Healthcare provider profile · identity verified

Thomas Michael Tambouratzis, MD

Internal Medicine · WASHINGTON, PA · NPI 1386604874

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	559	144
Lisinopril	Lisinopril	465	115
Levothyroxine Sodium	Levothyroxine Sodium	446	96
Amlodipine Besylate	Amlodipine Besylate	398	95
Gabapentin	Gabapentin	352	56
Pantoprazole Sodium	Pantoprazole Sodium	331	74
Metformin Hcl	Metformin Hcl	274	71
Pravastatin Sodium	Pravastatin Sodium	269	61
Simvastatin	Simvastatin	255	68
Eliquis	Apixaban	238	48
Losartan Potassium	Losartan Potassium	233	60
Omeprazole	Omeprazole	223	46
Furosemide	Furosemide	211	48
Metoprolol Tartrate	Metoprolol Tartrate	192	47
Atenolol	Atenolol	183	38
Hydrochlorothiazide	Hydrochlorothiazide	183	48
Albuterol Sulfate Hfa	Albuterol Sulfate	181	82
Metoprolol Succinate	Metoprolol Succinate	176	44
Tamsulosin Hcl	Tamsulosin Hcl	170	41
Allopurinol	Allopurinol	155	32
Potassium Chloride	Potassium Chloride	151	40
Sertraline Hcl	Sertraline Hcl	119	29
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	103	26
Meloxicam	Meloxicam	94	22
Terazosin Hcl	Terazosin Hcl	91	26
Warfarin Sodium	Warfarin Sodium	87	17
Clopidogrel	Clopidogrel Bisulfate	84	19
Trazodone Hcl	Trazodone Hcl	84	14
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	82	21
Carvedilol	Carvedilol	81	23
Spironolactone	Spironolactone	80	17
Cefuroxime	Cefuroxime Axetil	73	60
Glipizide	Glipizide	73	17
Azithromycin	Azithromycin	71	55
Paroxetine Hcl	Paroxetine Hcl	59	14
Methylprednisolone	Methylprednisolone	57	39
Rosuvastatin Calcium	Rosuvastatin Calcium	56	18
Finasteride	Finasteride	53	12
Glimepiride	Glimepiride	53	13
Alendronate Sodium	Alendronate Sodium	51	suppressed
Synthroid	Levothyroxine Sodium	50	13
Famotidine	Famotidine	49	14
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	48	13
Ezetimibe	Ezetimibe	48	14
Citalopram Hbr	Citalopram Hydrobromide	47	12
Tramadol Hcl	Tramadol Hcl	45	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	44	12
Zolpidem Tartrate	Zolpidem Tartrate	44	suppressed
Lorazepam	Lorazepam	43	12
Meclizine Hcl	Meclizine Hcl	40	16
Escitalopram Oxalate	Escitalopram Oxalate	39	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	39	11
Lovastatin	Lovastatin	39	suppressed
Alprazolam	Alprazolam	38	13
Metformin Hcl Er	Metformin Hcl	38	11
Repaglinide	Repaglinide	38	suppressed
Buspirone Hcl	Buspirone Hcl	37	suppressed
Duloxetine Hcl	Duloxetine Hcl	35	suppressed
Humalog Kwikpen U-100	Insulin Lispro	35	suppressed
Felodipine Er	Felodipine	34	suppressed
Montelukast Sodium	Montelukast Sodium	34	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	33	26
Fluticasone Propionate	Fluticasone Propionate	33	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	31	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	30	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	30	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	29	22
Fenofibrate	Fenofibrate Nanocrystallized	29	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	28	21
Glipizide Er	Glipizide	28	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	28	15
Valsartan	Valsartan	28	suppressed
Amoxicillin	Amoxicillin	27	22
Ropinirole Hcl	Ropinirole Hcl	27	suppressed
Breo Ellipta	Fluticasone/Vilanterol	26	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	26	suppressed
Hydralazine Hcl	Hydralazine Hcl	25	suppressed
Ibuprofen	Ibuprofen	25	suppressed
Lansoprazole	Lansoprazole	25	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	24	suppressed
Celecoxib	Celecoxib	23	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	suppressed
Colchicine	Colchicine	22	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	22	suppressed
Enalapril Maleate	Enalapril Maleate	22	suppressed
Ventolin Hfa	Albuterol Sulfate	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	20	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	20	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	20	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Benazepril Hcl	Benazepril Hcl	17	suppressed
Clonazepam	Clonazepam	17	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	17	suppressed
Nifedipine Er	Nifedipine	17	suppressed
Donepezil Hcl	Donepezil Hcl	16	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	16	suppressed
Pen Needles	Pen Needle, Diabetic	16	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	15	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Prednisone	Prednisone	15	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	14	suppressed
Ozempic	Semaglutide	14	suppressed
Fenofibrate	Fenofibrate,micronized	13	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	12	suppressed
Brilinta	Ticagrelor	12	suppressed
Dilt-Xr	Diltiazem Hcl	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	12	suppressed
Klor-Con M10	Potassium Chloride	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Mesalamine Dr	Mesalamine	12	suppressed
Naproxen	Naproxen	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Carbamazepine Er	Carbamazepine	11	suppressed
Cephalexin	Cephalexin	11	suppressed
Gemfibrozil	Gemfibrozil	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Linzess	Linaclotide	11	suppressed
Pyridostigmine Bromide	Pyridostigmine Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error